In general, life sciences companies are more confident in their capabilities to deal with R&D pipeline risks than supply chain and joint partner risks, according to Accenture’s 2013 Global Risk Management Study.
Nearly 60 percent of surveyed companies use a comprehensive set of risk categories in managing R&D pipeline risks, and more than half use risk analytics to address R&D-related risks. Even better news is that each approach we surveyed is employed by at least 40 percent of respondents.
Join me next week when I conclude my series by looking at how organizations are responding to the hot topic of regulatory change and healthcare reform.
To learn more: